1. Home
  2. LTRN vs INTS Comparison

LTRN vs INTS Comparison

Compare LTRN & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lantern Pharma Inc.

LTRN

Lantern Pharma Inc.

HOLD

Current Price

$3.05

Market Cap

49.9M

Sector

Health Care

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$0.42

Market Cap

24.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LTRN
INTS
Founded
2013
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.9M
24.0M
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
LTRN
INTS
Price
$3.05
$0.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$25.00
$4.33
AVG Volume (30 Days)
67.7K
3.2M
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.55
$0.19
52 Week High
$6.12
$3.17

Technical Indicators

Market Signals
Indicator
LTRN
INTS
Relative Strength Index (RSI) 37.63 47.99
Support Level $3.32 $0.35
Resistance Level $3.72 $0.43
Average True Range (ATR) 0.26 0.04
MACD -0.04 -0.01
Stochastic Oscillator 17.61 23.13

Price Performance

Historical Comparison
LTRN
INTS

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Share on Social Networks: